Telomelysin for Esophageal Cancer

Weill Cornell Medical College, New York, NY
Esophageal CancerTelomelysin - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug, OBP-301, to see if it can help treat stomach and esophageal cancer that has gotten worse despite other treatments.

Eligible Conditions
  • Esophageal Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 2 year

1 year
Disease control rate, as assessed by radiographic imaging
Duration of response, as assessed by radiographic imaging
Overall survival, as assessed by survival
Progression free survival, as assessed by radiographic imaging and survival.
2 year
Overall response rate, as assessed by radiographic imaging
Baseline, 2 years
Flow Cytometry
Change from baseline in T-cell response, as measured by TCR-sequencing of tumor biopsies
Change from baseline in tumor-immune microenvironment, as measured by bulk RNA sequencing and single-cell RNA sequencing.

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Telomelysin (OBP-301)
1 of 1

Experimental Treatment

41 Total Participants · 1 Treatment Group

Primary Treatment: Telomelysin · No Placebo Group · Phase 2

Telomelysin (OBP-301)
Experimental Group · 1 Intervention: Telomelysin · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 year

Who is running the clinical trial?

Oncolys BioPharma IncIndustry Sponsor
6 Previous Clinical Trials
74 Total Patients Enrolled
Weill Medical College of Cornell UniversityLead Sponsor
1,007 Previous Clinical Trials
1,330,882 Total Patients Enrolled
Manish Shah, MDPrincipal InvestigatorWeill Medical College of Cornell University
6 Previous Clinical Trials
390 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least four more months after starting treatment with OBP-301.
You must have already received two rounds of treatment for your advanced illness.

Frequently Asked Questions

How potentially hazardous is Telomelysin for individuals receiving treatment?

"After assessing the safety profile of Telomelysin, our team at Power has assigned it a rating of 2. This is because Phase 2 trials have only provided limited evidence in regards to its efficacy and lack data concerning its hazard potential." - Anonymous Online Contributor

Unverified Answer

How many participants are actively engaged in this clinical endeavor?

"Oncolys BioPharma Inc's clinical trial necessitates 41 participants that adhere to the set inclusion criteria. The study will take place at well-known medical centres including Dana-Farber Cancer Institute in Boston, Massachusetts and University of Pennsylvania in Philadelphia, Pennsylvania." - Anonymous Online Contributor

Unverified Answer

Is this trial open to enrollment of participants at present?

"Indeed, data indicates that the study is now recruiting participants; it was initially published on May 9th 2019 and last revised April 29th 2022. The medical trial seeks to enrol 41 patients from 4 distinct sites." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.